Neuromelanin content and striatal dopaminergic function in Parkinson’s disease

Lire cet article en français

Takeaway

  • Reduction of neuromelanin content in the substantia nigra pars compacta (SNc) in Parkinson’s disease (PD) only correlates with loss of striatal dopaminergic function in the clinically most-affected side of the brain.

Why this matters

  • The uneven pattern of association between SNc pigmentation and striatal dopaminergic function indicates a lag in disease progression or various pathological processes underlying PD.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.